BLSM insider transaction filings
BlossomHill Therapeutics, Inc. — 11 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen BLSM transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 6 filings by 12 insiders — 1,573,900 shares, $25,181,900 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: purchase of 625,000 shares @ $16.00 ($10,000,000) by ORBIMED ADVISORS LLC, filed 2026-08-12.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| GORDON CARL L — Director | 2 | 1 leg · 625,000 sh · $10,000,000 | — | 5 |
| ORBIMED ADVISORS LLC — Director & OrbiMed Capital GP VIII LLC — Director | 1 | 1 leg · 625,000 sh · $10,000,000 | — | 4 |
| Chen Bihua — Director, 10% owner & Cormorant Asset Management, LP — 10% owner & Cormorant Global Healthcare Master Fund, LP — 10% owner & Cormorant Private Healthcare Fund III LP — 10% owner & Cormorant Private Healthcare Fund V LP — 10% owner & Cormorant Private Healthcare Fund VI, LP — 10% owner | 1 | 1 leg · 312,500 sh · $5,000,000 | — | 5 |
| Schmid John P. — Director | 1 | 1 leg · 6,000 sh · $96,000 | — | — |
| Liptak Vincent Paul — General Counsel | 1 | 2 legs · 4,700 sh · $74,700 | — | 3 |
| Keyes Jason A — Chief Financial Officer | 1 | 1 leg · 700 sh · $11,200 | — | 1 |
| Cui Jingrong Jean — President and CEO, Director, 10% owner | 1 | — | — | 7 |
| Li Yishan — Executive Chairman, Director, 10% owner | 1 | — | — | 7 |
| Agrawal Sundeep — Director | 1 | — | — | 3 |
| Oxnard Geoffrey Raymond — Chief Medical Officer | 1 | — | — | 1 |
Recent Form 4 filings — BlossomHill Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VIII LLC — Director | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | GORDON CARL L — Director | Conversion (C): 1,039,996 · Conversion (C): 1,049,283 · Purchase (P): 625,000 @ $16 · Conversion (C): 1,039,996 (derivative) @ $0 · Conversion (C): 1,049,283 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Schmid John P. — Director | Purchase (P): 6,000 @ $16 | EDGAR |
| 2026-08-10 | 4 | GORDON CARL L — Director | Grant/award (A): 23,904 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Chen Bihua — Director, 10% owner Cormorant Asset Management, LP — 10% owner Cormorant Global Healthcare Master Fund, LP — 10% owner Cormorant Private Healthcare Fund III LP — 10% owner Cormorant Private Healthcare Fund V LP — 10% owner Cormorant Private Healthcare Fund VI, LP — 10% owner | Conversion (C): 1,599,993 · Conversion (C): 1,701,541 · Purchase (P): 312,500 @ $16 · Grant/award (A): 23,904 (derivative) @ $0 · Conversion (C): 1,599,993 (derivative) · Conversion (C): 1,701,541 (derivative) | EDGAR |
| 2026-08-10 | 4 | Agrawal Sundeep — Director | Conversion (C): 578,524 · Grant/award (A): 23,904 (derivative) @ $0 · Conversion (C): 578,524 (derivative) | EDGAR |
| 2026-08-10 | 4 | Liptak Vincent Paul — General Counsel | Purchase (P): 2,500 @ $15.80 · Purchase (P): 2,200 @ $16 · Conversion (C): 22,687 · Grant/award (A): 46,561 (derivative) @ $0 · Conversion (C): 22,687 (derivative) | EDGAR |
| 2026-08-10 | 4 | Keyes Jason A — Chief Financial Officer | Purchase (P): 700 @ $16 · Grant/award (A): 56,746 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Oxnard Geoffrey Raymond — Chief Medical Officer | Grant/award (A): 61,783 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Cui Jingrong Jean — President and CEO, Director, 10% owner | Conversion (C): 1,600,682 · Conversion (C): 113,435 · Conversion (C): 124,779 · Grant/award (A): 676,205 (derivative) @ $0 · Conversion (C): 1,600,682 (derivative) · Conversion (C): 113,435 (derivative) · +1 more | EDGAR |
| 2026-08-10 | 4 | Li Yishan — Executive Chairman, Director, 10% owner | Conversion (C): 1,600,682 · Conversion (C): 113,435 · Conversion (C): 124,779 · Grant/award (A): 112,701 (derivative) @ $0 · Conversion (C): 1,600,682 (derivative) · Conversion (C): 113,435 (derivative) · +1 more | EDGAR |
Recent 8-K events — BlossomHill Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BLSM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →